Sponsored by: GlobalData
- Multiple Myeloma
Date: 26 March
Days to go: 3
Time: 3PM London/11AM New York
Global Drug Forecast and Market Analysis to 2027
Multiple Myeloma is a cancer of abnormal plasma cells, a type of white blood cell that is normally responsible for producing antibodies in the bone marrow. It is the second most common hematological malignancy in the US, and constitutes less than 1% of all cancer types. The five-year survival rate is approximately 45%, and it is suggested that 1.9% of all cancer deaths can be attributed to multiple myeloma (NCI, 2014). Multiple myeloma is not considered curable, but is treatable, with many therapies being generic steroids, and chemotherapies. Significant improvements in progression-free survival and overall survival arrived with the introduction of the immunomodulatory (iMiD) agent Thalomid (thalidomide). In later years, the proteasome inhibitor(PI) Velcade (bortezomib), and the next generation IMiD Revlimid (lenalidomide) came to the market, revolutionizing myeloma treatment. Since the early 2000’s, multiple myeloma therapy has been dominated by these two agents, and they can be found in every setting of the disease, and in multiple combinations.
Multiple myeloma is still incurable, and although many patients live for many years with the disease under control, ultimately, all patients will at some point relapse. Patients with genetic risk factors will progress very quickly, and some patients have such aggressive disease that barely responds to therapy. The latest drugs approved in the US, including Pomalyst, Kyprolis, Ninlaro, and Empliciti have prolonged PFS and OS, but patients are still becoming refractory to these drugs. Currently the only therapy class that brings clinical benefit to patients who relapse on these agents are J&J's anti-CD38 monoclonal antibody Darzalex. With the increased adoption of Darzalex in the treatment paradigm, more patients are becoming refractory to Darzalex, which is an unmet need as currently there aren’t any marketed therapies which can provide benefit to patients whose disease relapses following treatment with Darzalex. The Phase III development pipeline, which includes novel therapies such as anti-BCMA biologics, selinexor, Venclexta, isatuximab, and Ygalo, will begin to address the unmet needs patients face and provide alternate treatment options to currently marketed therapies. However, further investigation and development will be required, as patients will still experience relapse.
In this webinar Volkan Gunduz, PhD, Senior Healthcare Analyst at GlobalData, will present the drug forecast and market analysis to 2027, drawing on key insights from GlobalData’s recently published report, Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027. The current treatment options and drug pipeline for multiple myeloma will be covered, including a discussion on GlobalData’s sales forecasts for the most impactful multiple myeloma therapies. The webinar will cover insights from various key opinion leaders (KOLs) on the current treatment options, pipeline drugs, the unmet needs, and the most promising R&D strategies. Fern Barkalow, PhD, Director of Oncology and Hematology at GlobalData will moderate the Q&A session following the presentation.
Senior Oncology and Hematology Analyst
Volkan Gunduz, PhD, is a Senior Oncology Analyst at GlobalData in Boston. He offers in-depth market intelligence and data interpretation within the oncology pharmaceuticals sector. Volkan completed his PhD in Genetics at Tufts University where he studied the role of Retinoblastoma tumor suppressor protein in bone development and cancer. He received a BSc in Molecular Biology and Genetics at Bilkent University, Turkey. Previous to joining GlobalData, he worked at Children’s Hospital Boston and New York University as a postdoctoral fellow working on projects that investigated the impact of dietary restriction on lung tumorigenesis and the gene network that regulates muscle stem cell identity.
Director of Oncology and Hematology
Fern Barkalow, PhD, is the Director of Oncology and Hematology at GlobalData in Boston. Fern has over 20 years of experience in the biopharmaceutical industry, as well as a research background in molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern then moved into the database group at Incyte Pharmaceuticals where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then joined the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs. Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine and Dentistry of New Jersey and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women’s Hospital.
Key Learning Objectives
- Learn how the multiple myeloma market dynamics are expected to change between 2017 and 2027 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and China)
- Gain in-depth insight about the late-stage multiple myeloma pipeline, including the products that are expected to dominate the market and the key drivers behind these.
- Understand the unmet needs that key opinion leaders (KOLs) have identified in the multiple myeloma treatment space and an analysis on whether the current pipeline will meet these needs.
- Learn about some of the key R&D strategies, growth drivers, and barriers in the multiple myeloma market across the 8MM.
- Senior Managers
- Associate Directors
- Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers